Editas Medicine Announces Executive & Board Changes
Ticker: EDIT · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1650664
Sentiment: neutral
Topics: executive-changes, board-changes, personnel
TL;DR
Editas Medicine shakes up leadership with new CMO and board members.
AI Summary
Editas Medicine, Inc. announced on December 16, 2024, a series of executive and board changes. These include the appointment of Dr. Michael A. Caligiuri as Chief Medical Officer and the election of Dr. David L. R. Gordon and Ms. Sarah E. Michael to its Board of Directors. The company also reported on compensatory arrangements for its named executive officers.
Why It Matters
These leadership and board adjustments at Editas Medicine could signal a strategic shift or a renewed focus on specific areas of the company's gene editing therapies.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- Dr. Michael A. Caligiuri (person) — Appointed Chief Medical Officer
- Dr. David L. R. Gordon (person) — Elected to Board of Directors
- Ms. Sarah E. Michael (person) — Elected to Board of Directors
- December 16, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Michael A. Caligiuri has been appointed as the new Chief Medical Officer.
Who were elected to the Board of Directors?
Dr. David L. R. Gordon and Ms. Sarah E. Michael were elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 16, 2024.
What is the principal executive office address for Editas Medicine, Inc.?
The principal executive office address is 11 Hurley Street, Cambridge, Massachusetts 02141.
What is the SIC code for Editas Medicine, Inc.?
The Standard Industrial Classification (SIC) code for Editas Medicine, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 689 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-12-17 16:17:32
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
Filing Documents
- edit-20241216.htm (8-K) — 24KB
- 0001650664-24-000144.txt ( ) — 145KB
- edit-20241216.xsd (EX-101.SCH) — 2KB
- edit-20241216_lab.xml (EX-101.LAB) — 21KB
- edit-20241216_pre.xml (EX-101.PRE) — 12KB
- edit-20241216_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: December 17, 2024 By: /s/ Gilmore O'Neill Gilmore O'Neill President and Chief Executive Officer